Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 4

Testosterone replacement therapy for older men

Authors Stephen E Borst, Thomas Mulligan

Published 15 January 2008 Volume 2007:2(4) Pages 561—566

DOI http://dx.doi.org/10.2147/CIA.S1609

Stephen E Borst, Thomas Mulligan

Geriatrics Research, Education, and Clinical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, USA

Abstract: Despite intensive research on testosterone therapy for older men, important questions remain unanswered. The evidence clearly indicates that many older men display a partial androgen deficiency. In older men, low circulating testosterone is correlated with low muscle strength, with high adiposity, with insulin resistance and with poor cognitive performance. Testosterone replacement in older men has produced benefits, but not consistently so. The inconsistency may arise from differences in the dose and duration of testosterone treatment, as well as selection of the target population. Generally, studies reporting anabolic responses to testosterone have employed higher doses of testosterone for longer treatment periods and have targeted older men whose baseline circulating bioavailable testosterone levels were low. Most studies of testosterone replacement have reported anabolic that are modest compared to what can be achieved with resistance exercise training. However, several strategies currently under evaluation have the potential to produce greater anabolic effects and to do so in a safe manner. At this time, testosterone therapy can not be recommended for the general population of older men. Older men who are hypogonadal are at greater risk for the catabolic effects associated with a number of acute and chronic medical conditions. Future research is likely to reveal benefits of testosterone therapy for some of these special populations. Testosterone therapy produces a number of adverse effects, including worsening of sleep apnea, gynecomastia, polycythemia and elevation of PSA. Efficacy and adverse effects should be assessed frequently throughout the course of therapy.
Keywords: aging, testosterone, hypogonadism, physical function

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion

Stefanini FR, Maia M, Falabella P, Pfister M, Niemeyer M, Kashani AH, Humayun MS, Koss MJ

Clinical Ophthalmology 2014, 8:847-856

Published Date: 6 May 2014

Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells

Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ

International Journal of Nanomedicine 2012, 7:4973-4982

Published Date: 14 September 2012

Rivaroxaban in atrial fibrillation

Giorgi MA, Miguel LS

Vascular Health and Risk Management 2012, 8:525-531

Published Date: 30 August 2012

Who coined the term “status gelasticus”? We did

Yu-tze Ng

Neuropsychiatric Disease and Treatment 2009, 5:405-406

Published Date: 16 July 2009

Population-based health promotion perspective for older driver safety: Conceptual framework to intervention plan

Sherrilene Classen, Ellen DS Lopez, Sandra Winter, Kezia D Awadzi, Nita Ferree, et al

Clinical Interventions in Aging 2007, 2:677-693

Published Date: 15 January 2008

Effect of estrogens on skin aging and the potential role of SERMs

Susan Stevenson, Julie Thornton

Clinical Interventions in Aging 2007, 2:283-297

Published Date: 15 October 2007

Neurite development in PC12 cells cultured on nanopillars and nanopores with sizes comparable with filopodia

Furqan Haq, Venkatramani Anandan, Charles Keith, Guigen Zhang

International Journal of Nanomedicine 2007, 2:107-115

Published Date: 15 April 2007

Vitamins in aging, health, and longevity

David R Thomas

Clinical Interventions in Aging 2006, 1:81-91

Published Date: 15 March 2006